American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients
Issued Date
2022-09-13
Resource Type
ISSN
24739529
eISSN
24739537
Scopus ID
2-s2.0-85138066187
Pubmed ID
35748885
Journal Title
Blood Advances
Volume
6
Issue
17
Start Page
4975
End Page
4982
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Advances Vol.6 No.17 (2022) , 4975-4982
Suggested Citation
Cuker A., Tseng E.K., Schunemann H.J., Angchaisuksiri P., Blair C., Dane K., DeSancho M.T., Diuguid D., Griffin D.O., Kahn S.R., Klok F.A., Lee A.I., Neumann I., Pai A., Righini M., Sanfilippo K.M., Siegal D.M., Skara M., Terrell D.R., Touri K., Akl E.A., Al Jabiri R., Al Jabiri Y., Boulos M., Brignardello-Petersen R., Charide R., Colunga-Lozano L.E., Dearness K., Darzi A.J., Karam S.G., Morgano G.P., Morsi R.Z., Philip B.A., Benitez Y.R., Stevens A., Solo K., Wiercioch W., Mustafa R.A., Nieuwlaat R. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances Vol.6 No.17 (2022) , 4975-4982. 4982. doi:10.1182/bloodadvances.2022007940 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87241
Title
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients
Author(s)
Cuker A.
Tseng E.K.
Schunemann H.J.
Angchaisuksiri P.
Blair C.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Kahn S.R.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Siegal D.M.
Skara M.
Terrell D.R.
Touri K.
Akl E.A.
Al Jabiri R.
Al Jabiri Y.
Boulos M.
Brignardello-Petersen R.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Karam S.G.
Morgano G.P.
Morsi R.Z.
Philip B.A.
Benitez Y.R.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Nieuwlaat R.
Tseng E.K.
Schunemann H.J.
Angchaisuksiri P.
Blair C.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Kahn S.R.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Siegal D.M.
Skara M.
Terrell D.R.
Touri K.
Akl E.A.
Al Jabiri R.
Al Jabiri Y.
Boulos M.
Brignardello-Petersen R.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Karam S.G.
Morgano G.P.
Morsi R.Z.
Philip B.A.
Benitez Y.R.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Nieuwlaat R.
Author's Affiliation
Ramathibodi Hospital
L’École de médecine
School of Medicine
American University of Beirut
The University of Jordan
McMaster University
University of Oklahoma Health Sciences Center
The University of Chicago
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
Saint Michael's Hospital University of Toronto
Leids Universitair Medisch Centrum
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Lincoln Medical and Mental Health Center
The Johns Hopkins Hospital
Universidad San Sebastián
Research and Development at United Health Group
Prohealth NY
L’École de médecine
School of Medicine
American University of Beirut
The University of Jordan
McMaster University
University of Oklahoma Health Sciences Center
The University of Chicago
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
Saint Michael's Hospital University of Toronto
Leids Universitair Medisch Centrum
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Lincoln Medical and Mental Health Center
The Johns Hopkins Hospital
Universidad San Sebastián
Research and Development at United Health Group
Prohealth NY
Other Contributor(s)
Abstract
Background: COVID-19–related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19. Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines. Results: The panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19–related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk. Conclusions: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19–related critical illness.